SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA reported a leadership change and strong preliminary 2025 results. The company promoted Ross Muken, currently President and a key executive for five years, to Chief Executive Officer effective July 1, 2026. He is expected to succeed co‑founder Dr. Jurgi Camblong, who will move to Executive Chairman of the Board, subject to election at the Annual General Meeting in June 2026.
For the quarter ended December 31, 2025, the company expects revenue of at least $21 million, about a 20% year‑over‑year increase, and more than 105,000 analyses on SOPHiA DDM, up 16% year‑over‑year. For the full year 2025, it expects revenue of about $77 million, an 18% year‑over‑year increase, and over 391,000 analyses, which it calls a company record. These figures are preliminary, unaudited estimates and may change as year‑end closing and audit work are completed, and the company’s independent auditors have not expressed an opinion on them.
SOPHiA GENETICS reported preliminary unaudited results showing fourth quarter 2025 revenue of at least $21 million, about 20% higher than a year earlier, with more than 105,000 SOPHiA DDM™ analyses, up 16% year-over-year. For full year 2025, revenue is expected to be about $77 million, roughly 18% growth, with over 391,000 analyses, a new company record.
For 2026, the company guides to full year revenue between $92 million and $94 million, implying about 20% to 22% growth, and an adjusted EBITDA loss between $29 million and $32 million. Results are preliminary and subject to completion of year-end closing and audit procedures.
The company also announced a leadership transition plan. Ross Muken, currently President and a long-time senior executive, will become CEO effective July 1, 2026, while co‑founder Jurgi Camblong is expected to move to the role of Executive Chairman, subject to election at the Annual General Meeting in June 2026. In addition, Kevin Puylaert will become Chief Sales Officer in January 2026.
A notice under Rule 144 reports a planned sale of 117,541 shares of common stock with an aggregate market value of $583,003.36. The shares relate to an issuer with 67,847,058 shares outstanding and are expected to be sold around 01/09/2026 on NASDAQ through Morgan Stanley Smith Barney LLC.
The securities to be sold consist of 25,500 founder shares acquired on 03/18/2021 and 92,041 shares received as restricted stock units on 01/18/2026. The notice also lists multiple prior 10b5-1 sales for JURGI CAMBLONG between 10/10/2025 and 01/08/2026, each showing the number of common shares sold and gross proceeds. By signing, the person for whose account the sale is made represents that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 for SOPH reports a proposed sale of 30,000 shares of common stock with an aggregate market value of $144,000.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/07/2026, and the stock is listed on NASDAQ, where 67,847,058 common shares are shown as outstanding.
The securities to be sold include 17,933 common shares acquired on 01/07/2026 via exercise of stock options for cash and 12,067 founder shares acquired on 03/18/2021. The filing also lists prior Rule 10b5-1 sales for JURGI CAMBLONG over the past three months, such as 16,948 common shares sold on 01/06/2026 for gross proceeds of 81,669.02 and 24,641 shares sold on 10/30/2025 for 123,942.82.
SOPH filed a Form 144 notice for a proposed sale of 3,866 common shares. The shares were acquired as restricted stock units on 10/02/2025 and are slated for sale on or about 10/03/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The filing lists an aggregate market value of $17,281.02 for the proposed shares and notes 67,579,560 shares outstanding.
The notice also details recent Rule 10b5-1 sales over the past three months: 09/19/2025 (381 shares; $1,211.35), 08/19/2025 (380; $1,304.01), 07/23/2025 (66; $226.38), 07/21/2025 (381; $1,349.54), and 07/07/2025 (1,703; $5,155.49).
SOPHiA GENETICS SA insider notice shows a proposed sale of 13,486 common shares, with an aggregate market value of $60,282.42, scheduled for 10/03/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 10/02/2025 from the issuer and the planned broker is Morgan Stanley Smith Barney LLC.
Recent sales by the same beneficial owner under a Rule 10b5-1 plan are disclosed: five separate sales totaling 10,016 shares between 07/07/2025 and 09/19/2025, generating gross proceeds shown per trade. The filer attests there is no undisclosed material adverse information and references Rule 10b5-1 instruction language in the form.
SOPHiA GENETICS SA insider filing notifies a proposed sale of 6,160 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/03/2025 and an aggregate market value of $27,535.20. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 and payment/settlement is shown as 10/02/2025. The filing also discloses recent 10b5-1 sales by Daan Guido Maria van Well totaling 4,996 shares sold on 07/07/2025, 07/21/2025, 07/23/2025, 08/19/2025, and 09/19/2025 with combined gross proceeds of $15,599.32. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
SOPHiA GENETICS SA (SOPH) filing a Form 144 notifies a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51 to be sold approximately on 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/02/2025 from the issuer and payment was recorded on 10/02/2025. The filing shows the seller previously completed Rule 10b5-1 sales totaling 5,337 shares across five transactions from 07/07/2025 through 09/19/2025, generating gross proceeds shown per transaction. The Form 144 includes the seller's representation that no undisclosed material adverse information exists and conforms to Rule 144 disclosure requirements.
SOPHiA GENETICS SA (SOPH) filed a Form 144 disclosing a proposed sale of 83,558 common shares through Morgan Stanley Smith Barney with an aggregate market value of $345,094.54 and an approximate sale date of 09/29/2025. The filing shows acquisition details: 42,729 shares as founders' shares acquired 03/18/2011 and 40,829 shares from restricted stock units dated 10/02/2025. The filer also reported multiple recent Rule 10b5-1 sales and an individual sale totaling 40,829 shares on 08/19/2025 with gross proceeds of $142,493.21. The notice includes the required representation regarding absence of undisclosed material information.